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Introduction: Antiplatelet agents, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statin drugs), angioten-
sin converting enzyme (ACE) inhibitors, and -adrenergic receptor blockers (-blockers) reduce cardiovascular risk and
mortality in patients with specific manifestations of cardiovascular disease and risk factors. Occlusive arterial disease, in
particular, coronary heart disease, is prevalent in patients with abdominal aortic aneurysm (AAA) and results in reduced
life expectancy. The purpose of this study was to investigate the prevalence of cardiovascular disease and risk factors in
patients with AAA. In particular, numbers of patients in whom pharmacologic therapy is indicated and numbers of
patients who are receiving adequate treatment were determined.
Methods: This was a prospective study of 313 patients with AAA in Leicestershire over the 15 months between September
2002 and December 2003.
Results: Data that enabled determination of an indication for antiplatelet agents and statin drugs were available for 262
patients (84%), and for a -blocker and ACE inhibitor for 313 patients (100%). An antiplatelet agent was indicated in 242
of 262 patients (92%), a statin drug was indicated in 196 of 262 patients (75%), a -blocker was indicated in 107 of 313
patients (34%), and an ACE inhibitor was indicated in 178 of 313 patients (57%). In patients with an indication, 146 of
242 patients (60%) were using an antiplatelet agent, 81 of 196 (41%) were using a statin drug, 41 of 313 (38%) were using
a -blocker, and 69 of 313 (39%) were using an ACE inhibitor.
Conclusion: Cardiovascular disease, for which there is evidence for the survival benefit of pharmacologic risk reduction, is
prevalent in patients with AAA. The data show that current treatment of cardiovascular risk is suboptimal and could be
improved, with an expected reduction in cardiovascular morbidity and mortality. ( J Vasc Surg 2004;40:691-7.)Antiplatelet agents, 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors (statin drugs), angiotensin-
converting enzyme (ACE) inhibitors, and -adrenergic
receptor blockers (-blockers) reduce cardiovascular risk in
patients with specific manifestations of atherosclerotic oc-
clusive arterial disease.1-4 Used individually, the relative risk
for fatal and nonfatal cardiovascular events is reduced by
approximately 25%, and when used in combination the risk
reduction may be as great as 75%.5 Atherosclerotic occlu-
sive arterial disease, in particular, coronary heart disease
(CHD), is prevalent in patients with abdominal aortic
aneurysm (AAA), and results in reduced life expectancy
compared with the rest of the population.6,7
Despite the strong association between AAA and car-
diovascular risk, the potential role of pharmacologic risk
reduction in patients with AAA has not been thoroughly
investigated, and remains unclear. There is sparse mention
of AAA in recommendations aimed at targeting patients for
cardiovascular risk reduction, and little is known about the
adequacy of current risk reduction in patients with AAA. To
test the hypothesis that cardiovascular risk reduction is
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doi:10.1016/j.jvs.2004.06.039consequently suboptimal in patients with AAA, the goal of
this study was to determine the number of patients with
AAA in whom a statin drug, antiplatelet agent, -blocker,
and ACE inhibitor is indicated and the number of patients
who are currently receiving adequate evidence based car-
diovascular risk reduction therapy.
METHODS
A prospective study was conducted in 313 patients with
AAA in Leicestershire over the 15 months between Sep-
tember 2002 and December 2003. Patients were recruited
during routine vascular surgery outpatient clinic visits, be-
fore or after AAA repair; at admission to hospital for AAA
repair; or during attendance at the Leicestershire AAA
screening program. The screening program identifies men
aged 65 from general practitioner (primary care physician)
patient lists, and they are offered abdominal ultrasound
scanning to measure the diameter of the aorta. Those with
a small AAA (5.5 cm) are followed up in the program
with scanning at 3-month to 12-month intervals, depend-
ing on diameter; and those with a large AAA (5.5 cm) are
referred to the vascular outpatient department for consid-
eration of surgical repair. All study patients had a general
practitioner, and patients attending the vascular surgery
outpatient clinic or admitted to hospital were under the
care of a vascular surgeon. Although no vascular medicine
specialist is present in the vascular surgery outpatient clinic,
lifestyle advice regarding smoking cessation and exercise is691
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priate.
A single investigator (G.L.) interviewed all patients,
using a standardized form, and information supplied by
patients was confirmed and supplemented with reference to
medical records. Data were collected on patient age and
sex, size of the AAA or size when repaired, smoking history,
previous diagnosis of myocardial infarction (MI), angina,
stroke, hypertension, peripheral vascular disease (PVD),
and diabetes, and a record was made of all medication being
taken at the time of recruitment into the study. The date
and results of blood lipid measurements were obtained
from the local pathology laboratory computer database.
This database comprehensively records the results of all
blood tests performed in the region. In each patient a blood
pressure measurement was taken in the right arm with the
patient seated. In patients in whom previous resting outpa-
tient blood pressure measurements were recorded in the
medical notes, mean blood pressure was calculated.
In patients with no history of occlusive arterial disease,
prediction of their risk for CHD over 10 years was esti-
mated with a CHD risk assessment calculator, based on the
Framingham Heart Study data.8 This risk assessment cal-
culation is based on attaching weighting to patient age, sex,
systolic and diastolic blood pressure, total and high-density
lipoprotein cholesterol (HDL-C) concentrations, diabetes,
and smoking habit. In the United Kingdom it is generally
accepted as a minimum standard of care that a statin drug is
indicated in the primary prevention of cardiovascular dis-
ease in patients without arterial occlusive disease with a 30%
or greater predicted risk for CHD in the next 10 years.9 An
antiplatelet agent is recommended in the primary preven-
tion of cardiovascular disease in patients with a 10-year risk
for CHD of 15% or greater, and we have used these criteria
as indication for an antiplatelet agent and statin drug in
patients with no evidence of occlusive arterial disease.9-11
Patients with occlusive arterial disease were considered
suitable for an antiplatelet agent, statin drug, and ACE
inhibitor in accordance with evidence from the Antithrom-
botic Trialists’ Collaboration, the Heart Protection Study,
and the Heart Outcomes Prevention Evaluation (HOPE),
which have demonstrated that all patients with occlusive
arterial disease, defined as a history of MI, angina, ischemic
stroke, or PVD, benefit from an antiplatelet agent, statin
drug, and ACE inhibitor.1-3 The HOPE study also dem-
onstrated that patients with diabetes plus an additional risk
factor (hypertension, smoking, high total cholesterol con-
centration, low HDL-C concentration, documented mi-
croalbuminuria) benefit from an ACE inhibitor, and we
have used these criteria as indication for treatment.3
-Blockers reduce mortality after MI, and their use in
patients with angina lowers the frequency of ischemic epi-
sodes.4 We have therefore considered patients with MI or
angina suitable to receive -blockers. Hypertension has
been defined as blood pressure 140/90 mm Hg or greater,
in accordance with the British Hypertension Society classi-
fication of hypertension.12 In addition, it is universally
accepted that smoking cessation is beneficial in all persons.Statistical analysis was performed with SPSS version 9,
and the 2 test was applied.
RESULTS
Two hundred eighty (89%) patients with AAA were
men, and 33 (11%) were women. Their median age was 71
years (range, 53-91 years). Seventy patients (22%) had
previously undergone AAA repair, and 243 patients (78%)
were undergoing AAA surveillance or consideration of
elective AAA repair at the time of the study. Mean AAA
diameter when recruited into the study or at the time of
AAA repair was 5.2 cm (range, 3-10 cm). Sixty-nine pa-
tients (22%) had a history of MI, 38 (12%) had angina but
no history of MI, 46 (15%) had a history of ischemic stroke,
and 80 (26%) had PVD.
Of the total 313 patients, 202 (65%) had a blood lipid
measurement in the previous 5 years; mean total choles-
terol concentration was 5.0 mmol/L (range, 2.9-8.5
mmol/L). Two hundred twenty-eight patients (73%) were
undergoing treatment of hypertension. Mean systolic
blood pressure was 146 mm Hg, and mean diastolic blood
pressure was 84 mm Hg. Two hundred eight patients
(66%) had systolic pressure 140 mm Hg or greater, or
diastolic pressure 90 mm Hg or greater. Twenty-one pa-
tients (7%) had diabetes. Twenty-seven (9%) patients de-
nied ever having smoked cigarettes, 75 (24%) were current
smokers, and 211 (67%) were former smokers. Patients
with a history of cigarette smoking had a mean pack-year
history of 38.2 years.
One hundred seventy-four patients (56%) had evidence
of occlusive arterial disease (MI, angina, PVD, stroke),
thereby having indication for an antiplatelet agent, statin
drug, and ACE inhibitor. One hundred seven of 174
patients (61%) had a history of MI or angina, and therefore,
in addition, had an indication for a -blocker (Table I;
Fig 1).
One hundred thirty-nine patients (44%) with AAA
were not known to have occlusive arterial disease, and
therefore an indication for a statin drug was based on
demonstration of a 10-year CHD risk of 30% or greater
(Fig 1). Fifty-one of 139 patients (37%) had not had a
recent blood lipid measurement. Eighty-eight patients
(63%) had total cholesterol and HDL-C concentration
measurements, thereby enabling 10-year CHD risk calcu-
lation. Mean 10-year CHD risk in the 88 patients was 22%
(range, 5%-53%). Twenty-two of the 88 patients (25%) had
a 10-year CHD risk of 30% or greater, thereby having an
indication for a statin drug. Of the 88 patients with a
determinable 10-year CHD risk, 68 (77%) had a 10-year
risk of 15% or greater, thereby having an indication for
antiplatelet prophylaxis. Statin drug and anitplatelet use,
depending on lipid measurement and indication, is shown
in Fig 2. Four patients without occlusive arterial disease had
diabetes and an additional cardiovascular risk factor, and in
accordance with the results of the HOPE study should use
an ACE inhibitor.
Table I displays the total numbers and percentages of
the 313 patients with AAA with indication for specific
A) w
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macologic risk reduction. Table II gives a breakdown of
vascular disease in the 313 patients with AAA, and the total
number and percentage of patients using an antiplatelet
agent, statin drug, ACE inhibitor, and -blocker.
There was no significant difference in adequacy of
treatment in patients who had undergone AAA repair com-
pared with those who had not. Comparing appropriate
treatment use in patients with an indication who had un-
dergone AAA repair versus those who had not undergone
AAA repair respectively revealed that antiplatelet agents
were used by 31 of 52 patients versus 115 of 190 patients (P
 .905), statin drugs were used by 18 of 42 patients versus
63 of 154 patients (P .82), -blockers were used by 11 of
25 patients versus 30 of 82 patients (P  .504), and ACE
inhibitors were used by 13 of 37 patients versus 56 of 141
patients (P  .611; 2 test).
DISCUSSION
The high prevalence of cardiovascular disease and risk
factors in patients with AAA means that most have an
Fig 1. Algorithm for pharmacologic cardiovascular risk
In all patients hypertension should be treated if present,
defined as myocardial infarction (MI), angina, periphera
heart disease; ACE, angiotensin converting enzyme.
Fig 2. Summary of lipid measurement, 10-year risk for c
use in 139 patients with abdominal aortic aneurysm (AAindication for an antiplatelet agent, statin drug, ACE inhibi-
tor, or -blocker. Seventy-five percent of 174 patients with
occlusive arterial disease and 88 patients without evidence of
occlusive arterial disease who had a lipid measurement had a
clear indication for a statin drug. If the 51 patients without
occlusive arterial disease who did not have a lipid measure-
ment are included in the analysis and it is assumed that the
proportion of the 51 patients with indication for a statin drug
is the same as in the patients without occlusive arterial disease
who had a lipid measurement (25%), then 67% would have an
indication for a statin drug. An antiplatelet agent was indicated
in 92% of patients with AAA, excluding the 51 patients who
had not had a lipid measurement. Again, if it assumed that the
proportion of the 51 patients with indication for an antiplate-
let agent is the same as in the patients without occlusive arterial
disease with a lipid measurement (77%), then 90% would have
an indication for an antiplatelet agent. Thirty-four percent of
patients had an indication for a -blocker, because of a history
of MI or angina, and 57% had an indication for an ACE
inhibitor, in accordance with the findings of the HOPE
study.3,4
tion in patients with abdominal aortic aneurysm (AAA).
smoking should be stopped. Occlusive arterial disease is
ular disease (PVD), or ischemic stroke. CHD, Coronary
ary heart disease (CHD), and antiplatelet and statin drug
ithout evidence of occlusive arterial disease.reduc
and
l vascoron
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is demonstrated; only 60% of patients were using an anti-
platelet agent, 41% were using a statin drug, 38% were
using a -blocker, and 39% were using an ACE inhibitor,
when indicated. In addition, 35% of patients had not had a
blood lipid measurement in the previous 5 years, and the
finding that 66% of patients had blood pressure 140/90
mm Hg or greater suggests that hypertensive control could
be improved. It is established that smoking cessation can
reduce the risk for MI by half, and the finding that one
fourth of the patients were current smokers highlights a
further opportunity for intervention to reduce cardiovascu-
lar risk.5
The presence of AAA is an indicator of high cardiovas-
cular risk.13,14 In 1980 Hertzer et al15 demonstrated that
patients who have undergone AAA repair have an annual
CHD mortality rate of 1.9% to 3.9%, and on this basis the
American 2001 Third Report of the National Cholesterol
Education Program Adult Treatment Panel (ATP-III) doc-
ument16 considers AAA to be a CHD risk equivalent, a
condition conferring a 20% or greater 10-year risk for
CHD. More recent studies have reported similar findings;
the United Kingdom Small Aneurysm Trial observed a 28%
Table I. Numbers and percentages of patients with occlus









n % n % n
Antiplatelet 174 100 129 74 68
Statin 174 100 79 45 22
-blocker 107 61 41 38 —
ACE inhibitor 174 100 67 39 4
In the consideration of patients in whom an antiplatelet agent or statin are ind
heart disease risk could not be established have been excluded.
OAD, Occlusive arterial disease.
*OAD is defined as myocardial infarction, angina, peripheral vascular diseas
Table II. Breakdown of associated manifestations of occlu









AAA only 139 44 24
AAA and PVD 38 12 8
AAA and CHD 63 20 36
AAA and stroke 23 7 8
AAA, PVD and CHD 27 9 18
AAA, PVD and stroke 6 2 2
AAA, CHD and stroke 8 3 3
AAA, CHD, Stroke and PVD 9 3 4
PVD, Peripheral vascular disease; CHD, coronary heart disease.incidence of mortality due to cardiovascular causes over an
8-year period, and 5-year survival rates between 60% and
74% have been demonstrated.7,18-20
The 2003 Heart Protection Study, a randomized con-
trolled trial of 20,536 patients aged 40 to 80 years with
occlusive arterial disease receiving 40 mg of simvastatin
daily or placebo demonstrated a reduction of approximately
25% in cardiovascular events and death in patients receiving
simvastatin, irrespective of baseline cholesterol level.2
There is growing evidence that statin drugs may also reduce
perioperative mortality in patients undergoing major vas-
cular surgical procedures, and long-term statin drug use
after AAA repair is associated with reduced all-cause and
cardiovascular mortality.21-23 Although ATP-III recom-
mends aggressive low-density lipoprotein cholesterol–
lowering therapy in patients with AAA, at present the
evidence for routine use of statin drugs in patients with
AAA is limited.16 This study demonstrates that most pa-
tients with AAA have associated cardiovascular disease for
which statin drugs confer survival benefit, strengthening
the case for routine statin therapy in most patients with
AAA.
rterial disease and without occlusive arterial disease, and
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77 17 25 242 92 146 60
25 2 9 196 75 81 41
— 107 34 41 38
3 2 50 178 57 69 39
, the 51 patients without occlusive arterial disease in whom 10-year coronary
schemic stroke.
arterial disease in patients with AAA and the numbers
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7 35 25 33 24 35 25
1 18 47 12 32 11 29
7 53 84 30 48 23 37
5 16 70 8 35 6 26
7 23 85 5 19 16 59
3 3 50 1 17 2 33
8 8 100 3 38 2 25
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irrespective of the severity of cardiovascular disease, and
cardiovascular benefit appears linearly dependent on abso-
lute cardiovascular risk.24 The Antithrombotic Trialists’
Collaboration in their meta-analyses of 287 randomized
trials of antiplatelet therapy versus control or one antiplate-
let regimen versus another demonstrated that an antiplate-
let agent reduces vascular events by 25% and vascular mor-
tality by one sixth in patients at increased risk for occlusive
vascular events.1 In primary prevention, aspirin use cannot
be justified without formal CHD risk estimation. The pre-
cise level of CHD risk necessary to justify antiplatelet
treatment is controversial. In the United States treatment
has been recommended in patients with 10-year CHD risk
levels of 6% and 10%, whereas in the United Kingdom
treatment in patients with risk of 15% or greater is generally
recommended.10,25,26 The estimation that the presence of
AAA confers a 20% or greater 10-year CHD risk provides
the rationale for the Antiplatelet in Vascular Surgery Con-
sensus Statement, which recommends that an antiplatelet
agent should be strongly considered in patients with AAA
without evidence of occlusive arterial disease.27 Our dem-
onstration that 92% of patients with AAA overall, and 77%
without evidence of occlusive arterial disease, have an indi-
cation for an antiplatelet agent supports this, but at present no
studies have determined the actual risk reduction associated
with antiplatelet use in patients with AAA.
In patients who have had an MI, a -blocker reduces
mortality by as much as 40%, and although there is no
evidence that -blocker use in patients with stable angina
improves survival, its use reduces the frequency of ischemic
episodes.4,28 Perioperative use of -blockers in patients at
high risk for cardiovascular disease or undergoing major
vascular surgery significantly lowers risk for MI and cardiac
death in the perioperative period and up to 2 years postop-
eratively.29,30
ACE inhibitors confer a proved survival benefit in pa-
tients with left ventricular systolic dysfunction, and improve
outcome in patients after MI.31 The HOPE study of 9297
patients at increased risk for vascular disease randomized to
receive either the ACE inhibitor ramipril or placebo ex-
panded the indication for treatment by demonstrating that
ramipril lowered the risk for MI, stroke, or cardiovascular
death by 22% in this patient group.3 We have demonstrated
that, by virtue of meeting the criteria laid out in the HOPE
study, more than half of patients with AAA should be using
an ACE inhibitor.3
Secondary prevention of cardiovascular disease has
been simplified and indications expanded by the demon-
stration that all patients with evidence of occlusive arterial
disease benefit from a statin drug, antiplatelet agent, and
ACE inhibitor.1-3 The effects of each agent appear to be
independent and additive, and it has been estimated that
when these are used in combination, two thirds to three
fourths of future vascular events can be prevented.5 In the 4
categories of treatment discussed, at least 1 non-proprietary
agent exists, resulting low-cost antiplatelet agents (aspirin
75 mg, $0.30 per 28 days), -blockers (propranolol 10 mg,$1.00 per 28 days), and ACE inhibitors (captopril 12.5 mg,
$2.00 per 28 days). However, at present, even the cheapest
statin drug is relatively expensive (fluvastatin 20 mg,
$23.00 per 28 days).32 The significant benefit of treatment,
combined with relative safety, has led to advocates of a
“polypill” suggesting that all patients older than 55 years or
those with manifestations of occlusive vascular disease
should take a combined pill containing a statin drug, aspi-
rin, 3 antihypertensive agents, and folic acid.33 However, at
present, cardiovascular risk reduction remains dependent
on identifying patients with indication for specific therapy.
The lack of studies investigating the potential benefit of
similar therapeutic measures in patients with AAA means
that little direct evidence exists for the benefit of pharma-
cologic cardiovascular risk reduction. Currently, identifica-
tion of patients with AAA who will benefit from using an
antiplatelet agent, statin drug, -blocker, or ACE inhibitor
depends on demonstrating associated cardiovascular dis-
ease for which there is evidence for their use. A recent study
of patients with PVD, a condition where there is clear
evidence of the benefit of pharmacologic cardiovascular risk
reduction, demonstrated that 93% of patients were using an
antiplatelet agent, 56% were using a statin drug, and 54%
were using an ACE inhibitor.34 Although this is clearly not
optimal treatment, it is superior to that in patients with
AAA. Typically in the United Kingdom vascular medicine
specialists are not present in the vascular surgery clinic, and
we would expect our results to be comparable with those in
most UK centers.
Side effects of the pharmacologic agents discussed are less
common than previously thought, and more therapeutic op-
tions within each drug class are becoming available. Patients
who are intolerant of aspirin can often tolerate alternative
antiplatelet agents.27,35 Symptoms sufficiently severe to stop
-blocker treatment occur in only 0.8% of patients, and,
although cited as a relative contraindication, most patients
with PVD satisfactorily tolerate a-blocker.36 Statin drugs are
safe, with liver failure and rhabdomyolysis the only serious
adverse effects, occurring at a rate of only 1 case per million
person-years.37 The only absolute contraindication to statin
drug use is active or chronic liver disease.37 ACE inhibitors are
well tolerated, with unwanted symptoms sufficiently severe to
stop treatment occurring in 0.1% of patients. However, they
can cause a decline in renal function or hypotension, and
therefore their use requires monitoring.3,36 The large proved
benefit of these therapies means that, unless an absolute con-
traindication to treatment exists, treatment should be initiated
and patient tolerance established.
The main limitation of this study is that the identification
of cardiovascular disease depends on the accuracy of a previous
diagnosis. Only a small number of patients have assessment of
left ventricular function available, so we have made no men-
tion of this in our analysis of patients who should receive an
ACE inhibitor. Although this approach will tend to underes-
timate the number of patients with an indication for cardio-
protective therapy, it enables an accurate evaluation of ade-
quacy of current cardiovascular risk factor reduction in patients
with known indications. We have used a 10-year CHD risk of
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no occlusive arterial disease, to avoid overestimating the number
of patients with indication for treatment. Generally, 10-year
CHD risk of 30% or greater is considered the minimum accepted
standard of care, and although initiating treatment at predicted
risk levels as low as 15% has been advocated, local recom-
mendations depend in part on available resources.38
Despite the strong association between AAA and car-
diovascular disease, identification and treatment of cardio-
vascular risk in patients with AAA is suboptimal. The grow-
ing popularity of AAA screening programs will result in the
increasing identification of patients with AAA and therefore
patients at high cardiovascular risk. Frequently patients
with AAA are not under the care of a cardiovascular physi-
cian, and provided long-term monitoring can be conducted
in primary care, the vascular surgery clinic would be an
appropriate setting for the initiation of treatment. This
approach will no doubt increase the life expectancy of
patients with AAA.
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